Capstone Asset Management Co. cut its position in Repligen Corporation (NASDAQ:RGEN) by 10.8% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 5,540 shares of the biotechnology company’s stock after selling 670 shares during the period. Capstone Asset Management Co.’s holdings in Repligen Corporation were worth $230,000 as of its most recent filing with the SEC.
Several other hedge funds have also recently bought and sold shares of RGEN. Karp Capital Management Corp purchased a new stake in Repligen Corporation during the first quarter worth approximately $506,000. Invictus RG purchased a new stake in Repligen Corporation during the first quarter worth approximately $233,000. Geode Capital Management LLC increased its stake in Repligen Corporation by 8.2% in the first quarter. Geode Capital Management LLC now owns 323,737 shares of the biotechnology company’s stock worth $11,395,000 after buying an additional 24,591 shares in the last quarter. BNP Paribas Arbitrage SA increased its stake in Repligen Corporation by 13.2% in the first quarter. BNP Paribas Arbitrage SA now owns 6,475 shares of the biotechnology company’s stock worth $228,000 after buying an additional 753 shares in the last quarter. Finally, Sei Investments Co. increased its stake in Repligen Corporation by 48.9% in the first quarter. Sei Investments Co. now owns 126,600 shares of the biotechnology company’s stock worth $4,456,000 after buying an additional 41,600 shares in the last quarter. 99.49% of the stock is currently owned by institutional investors.
Shares of Repligen Corporation (NASDAQ RGEN) traded up 1.26% during trading on Friday, hitting $40.21. The company had a trading volume of 266,076 shares. The firm has a 50 day moving average of $41.56 and a 200 day moving average of $37.05. Repligen Corporation has a 12-month low of $26.16 and a 12-month high of $46.81. The stock has a market cap of $1.50 billion, a PE ratio of 78.69 and a beta of 1.30.
Repligen Corporation (NASDAQ:RGEN) last posted its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported $0.20 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.15 by $0.05. The company had revenue of $32.40 million for the quarter, compared to the consensus estimate of $31.72 million. Repligen Corporation had a return on equity of 9.90% and a net margin of 15.61%. The firm’s quarterly revenue was up 11.0% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.16 EPS. On average, analysts forecast that Repligen Corporation will post $0.59 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Capstone Asset Management Co. Cuts Stake in Repligen Corporation (RGEN)” was originally published by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The original version of this piece can be accessed at https://transcriptdaily.com/2017/08/20/capstone-asset-management-co-cuts-stake-in-repligen-corporation-rgen.html.
A number of analysts have recently commented on RGEN shares. Zacks Investment Research raised Repligen Corporation from a “hold” rating to a “buy” rating and set a $46.00 price objective on the stock in a research note on Saturday, August 12th. BidaskClub downgraded Repligen Corporation from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, June 14th. Jefferies Group LLC reissued a “hold” rating and issued a $40.00 price objective (up previously from $33.00) on shares of Repligen Corporation in a research note on Wednesday, June 28th. William Blair started coverage on Repligen Corporation in a research note on Friday, July 21st. They issued an “outperform” rating on the stock. Finally, Janney Montgomery Scott boosted their price objective on Repligen Corporation from $42.00 to $47.00 in a research note on Friday, June 23rd. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. Repligen Corporation presently has an average rating of “Buy” and an average target price of $42.00.
About Repligen Corporation
Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.
Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Corporation (NASDAQ:RGEN).
Receive News & Ratings for Repligen Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corporation and related companies with MarketBeat.com's FREE daily email newsletter.